LEXX · Lexaria Bioscience Corp
United States · RS rating 84 · As of 2026-11-03
| Price | 4.03 USD |
|---|---|
| 1-day change | +10.7% |
| RS rating (overall / 1M / 3M / 12M) | 84 / 98 / 22 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 40 / 55 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +71.5% |
| Market cap (USD) | $23.4M |